TELA TELA Bio, Inc.

CIK 0001561921 50 ready 8-Ks latest April 30, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (7)

Ready 8-Ks 50

Latest filing June 11, 2026, 4:05 PM ET

Top materiality 0.85

Event mix earnings ×20 · other_material ×15 · leadership ×7

Sentiment 19 pos · 1 neg · 30 neu

Latest earnings ▼ miss 2025-Q3

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for TELA

Highest-materiality recent filing

TELA Bio secures $70M Perceptive term loan and launches approximately $11.9M equity offering; terminates MidCap facility

November 14, 2025, 6:59 PM ET debt materiality 0.85 neutral item 1.01 item 1.02 item 2.03 item 3.02 item 9.01 ◈ Equity Issuances

$60M initial loan funded Nov 14, 2025; optional $10M delayed draw. Matures Nov 14, 2030. Interest: 7.85% margin + greater of Reference Rate or 4.25%.
Issued Perceptive warrants for up to 2,333,333 shares at $1.11 exercise price, expiring 2035; warrants are cashless-exercisable and freely transferable.

Read filing →

April 30, 2026, 7:59 PM ET other material materiality 0.80 neutral item 2.02 item 5.02 ◈ executive_change ×7◈ Earnings Releases

TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed

Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close.
March 24, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

TELA Bio Q4 2025 revenue $20.9M (+18% YoY); guides FY26 growth at least 8%

Q4 2025 revenue $20.9M (+18% YoY); FY 2025 revenue $80.3M (+16% YoY).
March 20, 2026, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

TELA Bio receives Nasdaq deficiency notice for bid price below $1.00

Nasdaq notified TELA on March 17, 2026 that bid price closed below $1.00 for 30 consecutive business days.
November 14, 2025, 6:59 PM ET debt materiality 0.85 neutral item 1.01 item 1.02 item 2.03 item 3.02 item 9.01 ◈ Equity Issuances

TELA Bio secures $70M Perceptive term loan and launches approximately $11.9M equity offering; terminates MidCap facility

$60M initial loan funded Nov 14, 2025; optional $10M delayed draw. Matures Nov 14, 2030. Interest: 7.85% margin + greater of Reference Rate or 4.25%.
November 13, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

TELA Bio Q3 revenue $20.7M (+9% YoY); upsizes credit facility to $70M with Perceptive

Q3 revenue $20.7M (+9% YoY); net loss $8.6M vs $10.4M year ago; operating loss $7.6M.
August 11, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01

TELA Bio Q2 2025 revenue $20.2M (+26% YoY); net loss narrows to $9.9M; reaffirms FY2025 guidance $85M-$88M

Revenue $20.2M (+26% YoY); OviTex PRS product revenue up 53% YoY.
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

TELA Bio Q1 2025 revenue $18.5M (+12% YoY); net loss $11.3M; reiterates FY revenue guidance $85-88M

Revenue $18.5M, up 12% YoY; OviTex +15%, OviTex PRS +2%.
March 20, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

TELA Bio reports Q4 revenue $17.6M (+4% YoY); guides FY2025 revenue $85-88M (+23-27%)

FY2024 revenue $69.3M (+19% YoY); Q4 revenue $17.6M (+4% YoY) missed expectations due to transient disruptions.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

TELA Bio Q3 2024: revenue $19.0M (+26% YoY), net loss $10.4M; reaffirms FY2024 guidance

Revenue $19.0M, +26% YoY; OviTex unit sales +39%, OviTex PRS +44% YoY.
October 23, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 9.01

TELA Bio prices $37.3M public offering of 12M shares and pre-funded warrants at $2.25/share

Offering consists of 12M shares at $2.25/share and 5.8M pre-funded warrants at $2.2499 each, exercisable at $0.0001.
October 22, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01

TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts

Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.
August 12, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance

Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.
May 9, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

TELA Bio Q1 revenue $16.6M (+39% YoY); raises FY2024 guidance to $74.5M-$76.5M

Revenue $16.6M, up 39% YoY; 13th consecutive quarter of ≥35% growth.
April 15, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.

OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.
March 21, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 8.01 item 9.01 ◈ Earnings Releases ×2

TELA Bio reports record 2023 revenue $58.5M (+41% YoY); guides FY2024 $74-76M

Q4 revenue $17.0M (+46% YoY); full-year revenue $58.5M (+41% YoY).
March 20, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

TELA Bio sells NIVIS distribution rights to MiMedx for at least $8M, up to $12M

Initial $5.0M payment; future payments min $3.0M, max $7.0M based on NIVIS net sales over two years.
November 9, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

TELA Bio Q3 revenue $15.1M (+35% YoY); narrows FY2023 guidance to $57-60M

Revenue of $15.1M, up 35% YoY, marking 11th straight quarter of ≥35% growth.
August 9, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M

Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.
May 11, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

TELA Bio Q1 revenue $11.9M (+45% YoY); reaffirms FY2023 guidance $60M-$65M

Revenue $11.9M, up 45% YoY; OviTex revenue +42%, OviTex PRS +52%.
April 20, 2023, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01 ◈ Material Agreements

TELA Bio announces public offering of 4.75M shares at $9.50 per share; expects net proceeds ~$42.1M

Offered 4,750,000 shares at $9.50 per share; underwriters have 30-day option for 712,500 additional shares.
April 18, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02 ◈ Earnings Releases

TELA Bio preliminary Q1 revenue $11.9M, up 45% YoY; cash $30.1M

Revenue estimated at $11.9M for Q1 2023 vs $8.2M in Q1 2022, a 45% increase.
March 23, 2023, 7:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

TELA Bio receives FDA 510(k) clearance for OviTex PRS Long-Term Resorbable

FDA granted 510(k) clearance on March 23, 2023 for OviTex PRS Long-Term Resorbable.
March 21, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×3

TELA Bio Q4 revenue $11.6M (+39% YoY); FY2023 guidance $60-65M

Full-year 2022 revenue $41.4M (+41% YoY); net loss $44.3M.
November 9, 2022, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M

Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.
August 17, 2022, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

TELA Bio (TELA) raises ~$34.2M in public offering of 4.6M shares at $8.00

Underwriting agreement with Lake Street Capital Markets for 4M shares at $8.00/share; option for 600K additional shares exercised in full.
August 10, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M

Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.
May 31, 2022, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 1.02 item 2.03 item 9.01

TELA Bio enters $50M credit facility with MidCap; repays $33.2M OrbiMed debt

Borrowed $40.0M upfront from $50.0M term loan facility; unused $10M Tranche 2 conditional on reaching $65M net revenue by FY2023.
March 21, 2022, 7:59 PM ET earnings materiality 0.85 neutral item 2.02 item 7.01 item 9.01

TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M

Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).

Executive changes

Departed

Kurt Azarbarzin

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...

Departed

Vince Burgess

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...

Appointed

Guy Nohra

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...

Departed

Federica O'Brien

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board...

Appointed

Paul Thomas

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors...

Appointed

Guido Neels

Director

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director...

Departed

Doug Evans

Chairman of the Board

TELA · TELA Bio, Inc.

Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board...

Role change

Antony Koblish

President

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

Antony Koblish, the Company’s current President and Chief Executive Officer, will continue in his role as Chief Executive Officer, but as of the Effective Date will no longer hold the title of President.

Departed

Jeffrey Blizard

Director

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

Jeffrey Blizard, a member of the Board of Directors (the “ Board ”) of TELA Bio, Inc. (the “ Company ”), tendered his resignation from the Board, effective as of June 2, 2025.

Appointed

Jeffrey Blizard

President

TELA · TELA Bio, Inc.

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

the Board appointed Jeffrey Blizard as the new President of the Company, effective as of June 2, 2025

Appointed

Jeffrey Blizard

member of the Board of Directors

TELA · TELA Bio, Inc.

Effective: 2024-06-04
Filed: June 6, 2024, 7:59 PM ET

On June 4, 2024, TELA Bio, Inc. (the “ Company ”) appointed Jeffrey Blizard as a member of the Company’s Board of Directors (the “ Board ”).

Departed

John Nosenzo

Director

TELA · TELA Bio, Inc.

Effective: 2023-09-22
Filed: September 28, 2023, 7:59 PM ET

On September 22, 2023, John Nosenzo, a member of the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”), tendered his resignation from the Board, effective immediately.

Earnings & guidance

2025-Q3 EPS reported -$0.66 vs consensus -$0.20 ▼ miss (-225.1%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

19 positive 1 negative 30 neutral

source · TELA on sec.gov